Early cancer detection with multiplex immunoassays

Early cancer detection significantly improves outcomes, but many diagnostic tools lack the sensitivity to identify disease at its earliest stages. Single‑analyte assays often fall short because tumour development involves complex networks of interacting biomarkers that cannot be captured by one marker alone.

Multiplex immunoassays overcome this limitation by measuring multiple biomarkers simultaneously from small sample volumes. This approach provides system‑level insight into subtle biological changes linked to early tumour formation. R&D Systems™ Luminex® Assays use validated antibodies, optimised assay design, and flexible panels to accelerate biomarker discovery and advance translational oncology research.

Download this SelectScience guide to explore:

• How to meet the challenges of early cancer detection
• The 6 core benefits of protein biomarkers
• Multiplexed detection of tumor biomarker proteins
• The vital role of multiplex immunoassays

Resource details:

• Document type: SelectScience guide
• Page count: 18
• Read time: 27 mins
• Edition: 1st